Decision Matrix: Selecting a Unified Communications Vendor(Competitor Focus)

The Unified Communications Decision Matrix outlines the competitive dynamics within the UC market and guides IT decision makers to select a vendor based on its product strength, reputation among customers, and impact in the market. Datamonitor provides a holistic view of vendor capabilities and recommends those you should explore, consider and, most importantly, shortlist.

Report Highlights
Undoubtedly 2008 was a tumultuous year for the UC market. There were significant changes both to the competitive landscape and to the products and services offered by vendors. It is expected that 2009 will continue to see significant evolution in the market, particularly in regards to the positioning of vendors and their products.

Datamonitor believes that closer integration between collaboration suites and enterprise applications will be an interesting trend to watch in 2009. Beyond basic integration to create a unified inbox for email, sales leads and sign-off processes, there is tremendous scope for using collaboration tools to manage unstructured business processes.

Datamonitor expects consolidation to dominate the competitive landscape. However, it is not impossible that one of the large enterprise technology vendors will diversify its offering and acquire expertise and market share in the telecommunications industry.
[Studien Infos ausblenden]

CHAPTER 1 ABOUT THIS PROFILE 2
Executive summary 2
Quarterly news update 2
Company introduction 2
Company sales 2
Company financials 2
Key products and competitors 3
Data sourcing 3
Sales data 3
Analyst consensus 3
CHAPTER 2 EXECUTIVE SUMMARY 4
Key findings 4
Prescription pharmaceutical sales performance, 2001–13 5
Financial performance, 2001–13 6
Takeda: PharmaVitae forecasts at a glance 7
Strategic insight 8
Prospect of blockbuster genericization prompts wave of pipeline investment 8
Follow-on therapies vital in limiting impact of generic penetration 11
SWOT analysis 13
Strengths 13
Weaknesses 15
Opportunities 16
Threats 17
CHAPTER 3 QUARTERLY NEWS UPDATE 29
Product developments 29
Deals and alliances 32
M&A activity 33
Company announcements 33
Future product milestones 34
CHAPTER 4 COMPANY INTRODUCTION 35
Key findings 35
Background 36
Key corporate developments 36
Consumer health 38
Joint ventures 39
M&A history 39
Acquisition of Millennium Pharmaceuticals 39
Acquisition of Paradigm Therapeutics 41
Acquisition of Syrrx 41
M&A strategy 42
Pharmaceuticals business unit structure 43
Prescription pharmaceuticals 43
Consumer healthcare (OTC) 43
CHAPTER 5 COMPANY SALES 44
Key findings 44
Prescription pharmaceutical sales and growth rate analysis, 2001–13 46
Historical analysis 47
Forecast analysis 48
Product analysis 49
Product analysis, 2001–07 50
Product analysis, 2007–13 54
Therapy area analysis 59
Therapy area analysis, 2001–07 61
Therapy area analysis, 2007–13 62
Therapy area focus, 2001–13 63
Geographic analysis 64
Geographic analysis, 2001–07 65
Geographic analysis, 2007–13 66
Geographic focus, 2001–13 68
Launch/core/expiry analysis 69
Explanation of launch/core/expiry analysis 69
Launch analysis, 2007–13 70
Core analysis, 2007–13 72
Expiry analysis, 2007–13 73
Launch/core/expiry configuration, 2007–13 74
Molecule type analysis 75
Molecule type analysis, 2001–07 76
Molecule type analysis, 2007–13 76
Externalization analysis 77
Externalization analysis, 2001–07 78
Externalization analysis, 2007–13 79
CHAPTER 6 COMPANY FINANCIALS 81
Key findings 81
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001–07 82
Financial statements, 2001–07 84
Profit and loss account, 2001–07 84
Balance sheet, 2001–07 85
Operating costs and profit analysis 87
Operating costs and profit analysis, 2001–07 88
Operating cost ratio and profit margin analysis, 2001–07 89
Operating cost ratio and profit margin analysis, 2007–13 90
Operating costs and profit analysis, 2007–13 92
Return on capital employed analysis 93
Capital employed analysis, 2001–07 94
Return on capital employed (RoCE) analysis, 2001–07 96
Market capitalization analysis 98
Market capitalization analysis, 2001–07 98
Total shareholder returns analysis, 2001–07 99
CHAPTER 7 KEY PRODUCTS AND COMPETITORS 101
Key findings 101
Overview 102
Gastroenterology 103
TAK-390MR 103
Prevacid 108
Amitiza 114
Endocrine, metabolic & genetic disorders 118
Actos/ACTOplus met 118
SYR-322 125
Cardiovascular 130
Blopress/Blopress Comp 130
Oncology 137
Velcade 137
Central nervous system 142
Rozerem 142
CHAPTER 8 APPENDIX 148
R&D pipeline 148
References 150
Abbreviations 150
Exchange rates 152
[Inhaltsverzeichnis ausblenden]

Table 1: Vendors profiled in the Unified Communications Decision Matrix 9
Table 2: The Unified Communications Decision Matrix 11
Table 3: Unified Communications Decision Matrix: vendor scores summary 36
Figure 1: Unified Communications Decision Matrix 10
Figure 2: Expanded Unified Communications Decision Matrix 11
Figure 3: Market leaders analysis: technology 15
Figure 4: Market leaders analysis: end user sentiment 16
Figure 5: Market leaders analysis: market impact 17
Figure 6: Alcatel-Lucent UC radars 19
Figure 7: Avaya UC radars 21
Figure 8: Cisco UC radars 23
Figure 9: Interactive Intelligence UC radars 25
Figure 10: Nortel UC radars 27
Figure 11: ShoreTel UC radars 29
Figure 12: Siemens Enterprise Communications UC radars 31
Figure 13: TeleWare UC radars 33
[Tabellenverzeichnis ausblenden]